ReviewApplied microbiology and biotechnology2015
Metabolic engineering of Bacillus subtilis for terpenoid production.
Review in Applied microbiology and biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 54 citations in OpenAlex.
- Strategic selection of microbial cell factories for sustainable and application-specific terpenoid production.Frontiers in bioengineering and biotechnology · 2026Review
- Metabolic Engineering Strategy forFoods (Basel, Switzerland) · 2025Review
- Metabolic Engineering of Terpenoid Biosynthesis in Medicinal Plants: From Genomic Insights to Biotechnological Applications.Current issues in molecular biology · 2025Review
- The Effects of Dietary Supplementation with 25-Hydroxyvitamin D3 on the Antioxidant Capacity and Inflammatory Responses ofBiology · 2025Article
- Biosynthesis of Edible Terpenoids: Hosts and Applications.Foods (Basel, Switzerland) · 2025Review
- Enhancing lycopene production inFrontiers in bioengineering and biotechnology · 2025Article
- Microbial Squalene: A Sustainable Alternative for the Cosmetics and Pharmaceutical Industry - A Review.Engineering in life sciences · 2024Review
- Bacillus subtilis: current and future modification strategies as a protein secreting factory.World journal of microbiology & biotechnology · 2024Review
- A Programmable CRISPR/Cas9 Toolkit Improves Lycopene Production in Bacillus subtilis.Applied and environmental microbiology · 2023Article
- Metabolic engineering of Bacillus subtilis toward the efficient and stable production of CAMB Express · 2023Article
- Biotechnologies in Perfume Manufacturing: Metabolic Engineering of Terpenoid Biosynthesis.International journal of molecular sciences · 2023Review
- Positioning Bacillus subtilis as terpenoid cell factory.Journal of applied microbiology · 2021Review
- Genome Mining, Heterologous Expression, Antibacterial and Antioxidant Activities of Lipoamides and Amicoumacins from Compost-AssociatedMolecules (Basel, Switzerland) · 2021Article
- Impact of culture condition modulation on the high-yield, high-specificity and cost-effective production of terpenoids from microbial sources: A review.Applied and environmental microbiology · 2021Review
- Effectiveness of recombinant Escherichia coli on the production of (R)-(+)-perillyl alcohol.BMC biotechnology · 2021Article
- Production of Squalene inJournal of agricultural and food chemistry · 2020Article
- A regulated synthetic operon facilitates stable overexpression of multigene terpenoid pathway in Bacillus subtilis.Journal of industrial microbiology & biotechnology · 2020Article
- Manipulation of the precursor supply for high-level production of longifolene by metabolically engineered Escherichia coli.Scientific reports · 2019Article
- Overview of the Antimicrobial Compounds Produced by Members of theFrontiers in microbiology · 2019Review
- Metabolic Engineering ofFrontiers in microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Terpenoids are the largest group of small-molecule natural products, with more than 60,000 compounds made from isopentenyl diphosphate (IPP) and its isomer dimethylallyl diphosphate (DMAPP). As the most diverse group of small-molecule natural products, terpenoids play an important role in the pharmaceutical, food, and cosmetic industries. For decades, Escherichia coli (E. coli) and Saccharomyces cerevisiae (S. cerevisiae) were extensively studied to biosynthesize terpenoids, because they are both fully amenable to genetic modifications and have vast molecular resources. On the other hand, our literature survey (20 years) revealed that terpenoids are naturally more widespread in Bacillales. In the mid-1990s, an inherent methylerythritol phosphate (MEP) pathway was discovered in Bacillus subtilis (B. subtilis). Since B. subtilis is a generally recognized as safe (GRAS) organism and has long been used for the industrial production of proteins, attempts to biosynthesize terpenoids in this bacterium have aroused much interest in the scientific community. This review discusses metabolic engineering of B. subtilis for terpenoid production, and encountered challenges will be discussed. We will summarize some major advances and outline future directions for exploiting the potential of B. subtilis as a desired "cell factory" to produce terpenoids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.